- Home
- STTK vs FCCO Comparison
STTK vs FCCO Comparison
Compare STTK & FCCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FCCO
- Stock Information
- Founded
- STTK 2016
- FCCO 1994
- Country
- STTK United States
- FCCO United States
- Employees
- STTK N/A
- FCCO N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FCCO Major Banks
- Sector
- STTK Health Care
- FCCO Finance
- Exchange
- STTK Nasdaq
- FCCO Nasdaq
- Market Cap
- STTK 56.8M
- FCCO N/A
- IPO Year
- STTK 2020
- FCCO 1998
- Fundamental
- Price
- STTK $1.12
- FCCO $22.97
- Analyst Decision
- STTK Hold
- FCCO Buy
- Analyst Count
- STTK 3
- FCCO 1
- Target Price
- STTK $2.00
- FCCO $21.00
- AVG Volume (30 Days)
- STTK 182.2K
- FCCO 31.8K
- Earning Date
- STTK 02-27-2025
- FCCO 01-22-2025
- Dividend Yield
- STTK N/A
- FCCO 2.63%
- EPS Growth
- STTK N/A
- FCCO 2.46
- EPS
- STTK N/A
- FCCO 1.69
- Revenue
- STTK $6,435,000.00
- FCCO $62,732,000.00
- Revenue This Year
- STTK $313.04
- FCCO N/A
- Revenue Next Year
- STTK N/A
- FCCO $11.21
- P/E Ratio
- STTK N/A
- FCCO $13.19
- Revenue Growth
- STTK 382.75
- FCCO 6.16
- 52 Week Low
- STTK $0.94
- FCCO $15.40
- 52 Week High
- STTK $11.76
- FCCO $26.48
- Technical
- Relative Strength Index (RSI)
- STTK 43.75
- FCCO 35.98
- Support Level
- STTK $1.13
- FCCO $22.11
- Resistance Level
- STTK $1.39
- FCCO $24.07
- Average True Range (ATR)
- STTK 0.11
- FCCO 0.45
- MACD
- STTK 0.00
- FCCO -0.18
- Stochastic Oscillator
- STTK 18.18
- FCCO 36.29
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.